Arcadia Investment Management Corp MI Has $64,000 Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Arcadia Investment Management Corp MI trimmed its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 56.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,235 shares of the medical technology company’s stock after selling 5,523 shares during the period. Arcadia Investment Management Corp MI’s holdings in Alphatec were worth $64,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in shares of Alphatec by 7.3% during the fourth quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock worth $147,000 after purchasing an additional 660 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of Alphatec by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 19,025 shares of the medical technology company’s stock worth $287,000 after acquiring an additional 900 shares during the last quarter. RiverPark Advisors LLC raised its holdings in shares of Alphatec by 22.6% during the fourth quarter. RiverPark Advisors LLC now owns 5,033 shares of the medical technology company’s stock worth $76,000 after acquiring an additional 928 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Alphatec by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 20,900 shares of the medical technology company’s stock valued at $316,000 after purchasing an additional 1,000 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in Alphatec by 4.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 22,904 shares of the medical technology company’s stock worth $297,000 after purchasing an additional 1,030 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

Shares of Alphatec stock traded up $0.74 during trading on Thursday, reaching $11.34. The company’s stock had a trading volume of 4,209,159 shares, compared to its average volume of 1,699,122. Alphatec Holdings, Inc. has a one year low of $8.66 and a one year high of $19.14. The company has a debt-to-equity ratio of 6.54, a quick ratio of 1.99 and a current ratio of 2.86. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -7.32 and a beta of 1.48. The business’s fifty day moving average price is $13.21 and its 200-day moving average price is $13.53.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $138.48 million during the quarter, compared to the consensus estimate of $134.07 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. As a group, equities research analysts predict that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current year.

Insider Activity at Alphatec

In other Alphatec news, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $16.16, for a total value of $40,400.00. Following the sale, the executive vice president now directly owns 637,418 shares in the company, valued at approximately $10,300,674.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alphatec news, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total value of $40,400.00. Following the completion of the sale, the executive vice president now owns 637,418 shares in the company, valued at approximately $10,300,674.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO John Todd Koning sold 37,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total value of $480,750.00. Following the sale, the chief financial officer now owns 393,356 shares in the company, valued at $5,042,823.92. The disclosure for this sale can be found here. Insiders sold a total of 285,069 shares of company stock worth $3,971,495 in the last ninety days. 29.12% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently commented on ATEC. Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Monday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Alphatec in a report on Wednesday. Wells Fargo & Company started coverage on Alphatec in a research report on Friday, February 9th. They issued an “overweight” rating and a $26.00 price target for the company. Finally, Piper Sandler decreased their price target on Alphatec from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.